THE EFFECT OF AZOLOANNELED TETRAZINES ON PRIMARY BREAST CANCER CELL CULTURE AND THE SAOS CELL LINE
DOI:10.22138/2500-0918-2024-21-1-62-71
A.S. Mogilenskikh¹,², A.P. Suslonova², S.G. Tolshina³,
S.V. Sazonov¹,², S.M. Demidov¹,²
¹Institute of Medical Cell Technologies, Yekaterinburg, Russian Federation;
²Federal State Budgetary Educational Institution of Higher Education Ural State Medical University of the Ministry of Health of the Russian Federation,
Yekaterinburg, Russian Federation;
³Postovsky Institute of Organic Synthesis, Ural Branch of RAS,
Yekaterinburg, Russian Federation
Keywords:
azoloanneled tetrazines, breast cancer, primary culture, SAOS
There is no conflict of interest.
Contact details of the corresponding author:
Sergey V. Sazonov
prof-ssazonov@yandex.ru
Received 31.01.2024
For citation:
Mogilenskikh A.S., Suslonova A.P., Tolshina S.G., Sazonov S.V., Demidov S.M. The effect of azoloanneled tetrazines on primary breast cancer cell culture and the SAOS cell line. [Online] Vestn. Ural. Med. Akad. Nauki. = Journal of Ural Medical Academic Science. 2024, Vol. 21, no. 1, pp. 62–71. DOI:10.22138/2500-0918-2024-21-1-62-71 (In Russ)
REFERENCES
1. Merabishvili V.M. The state of cancer care in Russia: breast cancer among the female population. Morbidity, mortality, reliability of accounting, detailed localization and histological structure (population study at the federal district level). Issues of oncology. 2022. Vol. 68, No. 3
2. Gao L., Wu Z.X., Assara, Y.G., Chen Z.S., Wang L. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat. DOI:10.1016/j.drup.2021.100770
3. Zhang H, Wang Y, Liu X, Li Y. Progress of long noncoding RNAs in anti-tumor resistance. Pathol Res Pract. 2020. 216(11). DOI:10.1016/j.prp.2020.153215.
4. Karabina E.V., Lyubchenko L.N., Davydov M.M. Mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer unrelated to the T790M mutation and their significance in clinical practice. Advances in molecular oncology 2018. 5(3).pp. 17-24.
5. Shawali A. S., Tawfik N. M. Novel facile synthesis of imidazo[l,2-b][l,2,4,5]tetrazines with potential antimicrobial activity. Arch. Pharm. Res. 2009. V. 32. N 7. P. 975-982.
6. Pat. 2462466 RF, IPC From 07 D 487/04. Substituted azolo[1,2,4,5]tetrazines are inhibitors of actinobacterial serine-threonine protein kinases. O.B. Becker, V.N. Danilenko, R.I. Ishmetova, G.L. Rusinov, S.G. Tolstoy, V.N. Charushin, D.A. Maslov. The applicant and the patent holder are the Autonomous non-profit organization «BIOAN». publ. 09/27/2012, Issue No. 27.
7. Becker O.B., Danilenko V.N., Korotina A.V., Ishmetova R.I., Rusinov G.L., Thickness S.G., Charushin V.N., Maslov D.A.. Pat. 2545458 RF, IPC C 07 D 487/04. Anti-tuberculosis drug: composition of imidazo[1,2-b]tetrazine with pyrazinamide. The applicant and the patent holder are the Autonomous Non-profit organization «BIOAN»; publ. 03/27/2015, Issue No. 9.
8. Maslov D.A., Korotina A.V., Shur K.V., Vatlin A.A., Bekker O.B., Tolshchina S.G., et. al. Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines. Eur. J. Med. Chem. 2019. V. 178. P. 39-47.
9. Mohan J. Heterocyclic systems containing bridgehead nitrogen atom. Facile synthesis and biological activity of spiro [cycloheptane-1,7’(8’H)-[6H]pyrazolo[3’,4’:4,5]thiazolo[3,2-b]-s-tetrazines]. Ind. J. Heterocycl. Chem. 2005. V. 15. P. 187-188.
10. Ishmetova R.I., Ignatenko N.K., Belyaninova I.A. Synthesis and antifungal activity of 3-substituted imidazo[1,2-b][1,2,4,5]tetrazines. Izv. AN. Ser. chem. – 2015. No. 9. pp. 2100-2105.
11. Korotina A.V., Tolshchina S.G., Ishmetova R.I., Evstigneeva N.P., Gerasimova N.A., Zilberberg N.V. et al. Synthesis of novel [1,2,4]triazolo[1,5-b][1,2,4,5]tetrazines and investigation of their fungistatic activity. Beilstein J. Org. Chem. 2022. V. 18. P. 243–250.
12. Xu F., Yang Z.Z., Jiang J.R., Pan W.G., Yang X.L., Wu J.Y. et al. Jiang Synthesis, antitumor evaluation and molecular docking studies of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives. Bioorg. Med. Chem. Lett. 2016. V.26. N 13.P. 3042-3047.
13. Xu F., Yang Z.Z., Ke Z.L., Xi L.M., Yan Q.D., Yang W.Q. Synthesis, antitumor evaluation and 3D-QSAR studies of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives. Bioorg. Med. Chem. Lett. 2016. V. 26. P. 4580-4586.
14. Becker O.B., Danilenko V.N., Ignatenko N.K., Ishmetova R.I., Rusinov G.L., Thickness S.G. Pat. 2527258 Russian Federation, MPC C 07 D 487/04. 6-Substituted 3-azolylimidazo[1,2-b][1,2,4,5] tetrazines exhibiting antitumor activity / applicant and patent holder Autonomous non-profit organization «BIOAN»; publ. 08/27/2014, Issue No. 24.
15. Mezhevova I.V., Sitkovskaya A.O., Kit O.I. Primary cultures of tumor cells: modern methods of obtaining and maintaining in vitro. South Russian Journal of Oncology. 2020;1(3):36-49.
16. Mogilenskikh A.S., Sazonov S.V. Creation of breast carcinoma cell lines. Genes and cells. 2021 No.1. Vol.16, pp.15-23
17. Minafra L., Norata R., Bravatà V. Massimo V., Carmelo L., Cecilia G. & Cristina M. Unmasking epithelial-mesenchymal transition in a breast cancer primary culture: a study report. BMC Res Notes. 2012; 5:343.
18. Sazonov S.V. Brilliant A.A., Fadeev F.A., Demidov S.M., Leontiev S.L. The first experience in the cultivation of breast cancer cells. Bulletin of the Ural medical Academic science. 2018.Volume 15. No.6. pp. 860-867, DOI:10.22138/2500-0918-2018-15-6-860- 867
19. Mogilenskikh A. S., Grebenyuk E. V., Sazonov S. V., Shamshurina E.O., Konyshev K.V. The experience of obtaining a breast cancer cell culture from a tumor of the luminal B subtype. Bulletin of the Ural Medical Academic Science. – 2022. – Vol. 19, No. 1. – pp. 4-13. – DOI 10.22138/2500-0918-2022-19-1-4-13
20. Popova E.A., Protas A.V., Trifonov R.E. Tetrazole Derivatives as Promising Anticancer Agents. Anticancer Agents Med Chem. 2018; 17(14):1856-1868. DOI:10.2174/1871520617666170327143148.
21. Liu D., Yang J.G., Cheng J., Zhao L.X. Synthesis and antitumor activity of 3-methyl-4-oxo-3,4-dihydroimidazo [5,1-d][1,2,3,5]tetrazine-8-carboxylates and -carboxamides. Molecules. 2010;15(12):9427-37. DOI:10.3390/molecules15129427.
22. Liu J., Qiu L, Xia J., Chen S., Yu X., Zhou Y. ZGDHu-1 for cancer therapy. Oncol Lett. 2017; 14 (6):6334-6340. DOI:10.3892/ol.2017.7096.
23. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007 Jun;35 (4):495-516. DOI:10.1080/01926230701320337.
Authors
Anna S. Mogilenskikh
Institute of Medical Cell Technologies
Researcher
annasajler@yandex.ru
Yekaterinburg, Russian Federation
Anastasia P. Suslonova
Federal State Budgetary Educational Institution of Higher Education Ural State Medical University of the Ministry of Health of the Russian Federation
2nd year student of the Pediatric Faculty
asya.pin@yandex.ru
Yekaterinburg, Russian Federation
Svetlana G. Tolshina
Laboratory of Heterocyclic Compounds, Postovsky Institute of Organic Synthesis, Ural Branch of RAS
PhD, Senior Researcher at the Laboratory of Heterocyclic Compounds
kochevasg@gmail.com
Yekaterinburg, Russian Federation
Sergey V. Sazonov
Federal State Budgetary Educational Institution of Higher Education Ural State Medical University of the Ministry of Health of the Russian Federation
Head of the Department of Histology, Doctor of Medical Sciences, Professor
prof-ssazonov@yandex.ru
Yekaterinburg, Russian Federation
Sergey M. Demidov
Federal State Budgetary Educational Institution of Higher Education Ural State Medical University of the Ministry of Health of the Russian Federation
Head of the Department of Oncology and Radiation Diagnostics, Doctor of Medical Sciences, Professor
demidov@gkb40.ur.ru
Yekaterinburg, Russian Federation